642 related articles for article (PubMed ID: 26096370)
1. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.
Pittock SJ; Lucchinetti CF
Ann N Y Acad Sci; 2016 Feb; 1366(1):20-39. PubMed ID: 26096370
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Hinson SR; Lennon VA; Pittock SJ
Handb Clin Neurol; 2016; 133():377-403. PubMed ID: 27112688
[TBL] [Abstract][Full Text] [Related]
3. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
4. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders.
Iorio R; Papi C
Handb Clin Neurol; 2021; 181():173-186. PubMed ID: 34238456
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
8. Neurological autoimmunity targeting aquaporin-4.
Hinson SR; McKeon A; Lennon VA
Neuroscience; 2010 Jul; 168(4):1009-18. PubMed ID: 19699271
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.
Hinson SR; Pittock SJ; Lucchinetti CF; Roemer SF; Fryer JP; Kryzer TJ; Lennon VA
Neurology; 2007 Dec; 69(24):2221-31. PubMed ID: 17928579
[TBL] [Abstract][Full Text] [Related]
10. Sera from patients with seropositive neuromyelitis optica spectral disorders caused the degeneration of rodent optic nerve.
Matsumoto Y; Kanamori A; Nakamura M; Takahashi T; Nakashima I; Negi A
Exp Eye Res; 2014 Feb; 119():61-9. PubMed ID: 24374258
[TBL] [Abstract][Full Text] [Related]
11. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
Misu T; Fujihara K; Itoyama Y
Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
[TBL] [Abstract][Full Text] [Related]
12. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Roemer SF; Parisi JE; Lennon VA; Benarroch EE; Lassmann H; Bruck W; Mandler RN; Weinshenker BG; Pittock SJ; Wingerchuk DM; Lucchinetti CF
Brain; 2007 May; 130(Pt 5):1194-205. PubMed ID: 17282996
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
Sato DK; Nakashima I; Takahashi T; Misu T; Waters P; Kuroda H; Nishiyama S; Suzuki C; Takai Y; Fujihara K; Itoyama Y; Aoki M
Neurology; 2013 Jun; 80(24):2210-6. PubMed ID: 23677744
[TBL] [Abstract][Full Text] [Related]
15. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
16. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System.
Abe Y; Yasui M
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454180
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis.
Seay M; Rucker JC
Asia Pac J Ophthalmol (Phila); 2018; 7(4):229-234. PubMed ID: 29766684
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
